Press release
Feb 8, 2022

Sosei Heptares announces nomination of new disease target by Takeda under strategic multi-target research, development and commercialization partnership


•       Sosei Heptares receives undisclosed milestone payment from Takeda as collaborative progress continues to be made 

 

Tokyo, Japan and Cambridge, UK, 8 February 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been notified by its partner Takeda Pharmaceutical Company Limited (“Takeda”) that a new disease target has been nominated under their ongoing 2019 partnership agreement. Sosei Heptares will receive an undisclosed payment from Takeda for achieving this milestone.

The multi-target research, development and commercialization partnership between the companies is making good progress with early research milestones being met through the powerful combination of Sosei Heptares’ proprietary GPCR-focused structure-based drug design capabilities with Takeda’s extensive discovery, development and therapeutic area expertise. The partnership is directed towards the discovery of novel therapeutic agents against multiple GPCR targets nominated by Takeda, with an initial focus on gastro-intestinal diseases.

Shinichi Tamura, President and CEO of Sosei Heptares, commented “We are delighted to announce the achievement of this milestone from our ongoing partnership with Takeda. The collaboration has been very productive thus far, with a strong working relationship being established and multiple early milestones being reached. I look forward to seeing further progress from this partnership as we look to deliver new medicines for gastro-intestinal diseases.”

As per the agreement, Takeda is responsible for developing and commercializing potential new medicines for each novel target and will have exclusive global rights to these agents. Sosei Heptares has received upfront and multiple early research milestone payments, and is eligible to receive additional future development, commercialization and net sales-based payments that may exceed $1.2 billion. Sosei Heptares is also eligible to receive tiered royalties on net sales of any licensed products by Takeda resulting from the partnership. 

 

-ENDS-


 DOWNLOAD PDF